PepGen Inc. (PEPG)

In the past six months, PepGen's stock price was impacted by several events. On March 30, 2026, the company announced topline results from the Phase 2 FREEDOM2-DM1 study, which led to a stock price drop due to disappointing splicing correction data. On March 4, 2026, the U.S. FDA placed a partial clinical hold on the FREEDOM2 trial, causing the stock to decline. On November 12, 2025, PepGen reported positive results from the FREEDOM study and announced a $115 million financing round.

As a clinical-stage biotechnology company, PepGen Inc. does not exhibit traditional demand seasonality. Stock performance may show seasonality influenced by market factors and investor behavior. Demand for PepGen's future products will be driven by disease prevalence, clinical efficacy, regulatory approvals, and market access.

PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurological diseases. Their core technology is the Enhanced Delivery Oligonucleotide (EDO) platform, which enhances the uptake, activity, and tolerability of oligonucleotide therapeutics. The company's pipeline includes PGN-EDODM1 for myotonic dystrophy type 1 (DM1) and PGN-EDO51, PGN-EDO53, PGN-EDO45, and PGN-EDO44 targeting Duchenne muscular dystrophy (DMD).

PepGen Inc. is headquartered in Boston, Massachusetts, United States. Clinical trials are conducted in multiple countries, including the United States, the United Kingdom, Canada, South Korea, Australia, and New Zealand. The company also collaborates with academic institutions and clinical centers across the United States.

PepGen Inc.'s brand reputation has been affected by clinical trial results and regulatory actions. Disappointing Phase 2 clinical trial data and a partial clinical hold by the FDA negatively impacted investor confidence. Previously, compelling data from the Phase 1 FREEDOM trial had reinforced confidence in their EDO platform. Analysts currently have a "Moderate Buy" consensus rating for PepGen.

PepGen Inc. has a diverse ownership structure including institutional, insider, and public/retail investors. Major institutional owners include RA Capital Management, L.P., Viking Global Investors Lp, and Commodore Capital Lp. Insiders own approximately 37.08% of the company's stock, while institutional investors hold between 0.02% and 7.50%. Public companies and individual investors own approximately 55.43% of the stock. Peter Kolchinsky owns the most shares.